Cargando…

Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker

Immunotherapy, and in particular immune-checkpoints blockade therapy (ICB), represents a new pillar in cancer therapy. Antibodies targeting Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Programmed Death 1 (PD-1)/Programmed Death Ligand-1 (PD-L1) demonstrated a relevant clinical value in a large numb...

Descripción completa

Detalles Bibliográficos
Autores principales: Signorelli, Diego, Giannatempo, Patrizia, Grazia, Giulia, Aiello, Marco Maria, Bertolini, Federica, Mirabile, Aurora, Buti, Sebastiano, Vasile, Enrico, Scotti, Vieri, Pisapia, Pasquale, Cona, Maria Silvia, Rolfo, Christian, Malapelle, Umberto, Group, Immune-Oncology YOUNG
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507101/
https://www.ncbi.nlm.nih.gov/pubmed/31179334
http://dx.doi.org/10.1155/2019/9056417
_version_ 1783416959603310592
author Signorelli, Diego
Giannatempo, Patrizia
Grazia, Giulia
Aiello, Marco Maria
Bertolini, Federica
Mirabile, Aurora
Buti, Sebastiano
Vasile, Enrico
Scotti, Vieri
Pisapia, Pasquale
Cona, Maria Silvia
Rolfo, Christian
Malapelle, Umberto
Group, Immune-Oncology YOUNG
author_facet Signorelli, Diego
Giannatempo, Patrizia
Grazia, Giulia
Aiello, Marco Maria
Bertolini, Federica
Mirabile, Aurora
Buti, Sebastiano
Vasile, Enrico
Scotti, Vieri
Pisapia, Pasquale
Cona, Maria Silvia
Rolfo, Christian
Malapelle, Umberto
Group, Immune-Oncology YOUNG
author_sort Signorelli, Diego
collection PubMed
description Immunotherapy, and in particular immune-checkpoints blockade therapy (ICB), represents a new pillar in cancer therapy. Antibodies targeting Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Programmed Death 1 (PD-1)/Programmed Death Ligand-1 (PD-L1) demonstrated a relevant clinical value in a large number of solid tumors, leading to an improvement of progression free survival and overall survival in comparison to standard chemotherapy. However, across different solid malignancies, the immune-checkpoints inhibitors efficacy is limited to a relative small number of patients and, for this reason, the identification of positive or negative predictive biomarkers represents an urgent need. Despite the expression of PD-L1 was largely investigated in various malignancies, (i.e., melanoma, head and neck malignancies, urothelial and renal carcinoma, metastatic colorectal cancer, and pancreatic cancer) as a biomarker for ICB treatment-patients selection, it showed an important, but still imperfect, role as positive predictor of response only in nonsmall cell lung cancer (NSCLC). Importantly, other tumor and/or microenvironments related characteristics are currently under clinical evaluation, in combination or in substitution of PD–L1 expression. In particular, tumor-infiltrating immune cells, gene expression analysis, mismatch- repair deficiency, and tumor mutational landscape may play a central role in predicting clinical benefits of CTLA-4 and/or PD-1/PD-L1 checkpoint inhibitors. In this review, we will focus on the clinical evaluation of emerging biomarkers and how these may improve the naïve vision of a single- feature patients-based selection.
format Online
Article
Text
id pubmed-6507101
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-65071012019-06-09 Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker Signorelli, Diego Giannatempo, Patrizia Grazia, Giulia Aiello, Marco Maria Bertolini, Federica Mirabile, Aurora Buti, Sebastiano Vasile, Enrico Scotti, Vieri Pisapia, Pasquale Cona, Maria Silvia Rolfo, Christian Malapelle, Umberto Group, Immune-Oncology YOUNG Biomed Res Int Review Article Immunotherapy, and in particular immune-checkpoints blockade therapy (ICB), represents a new pillar in cancer therapy. Antibodies targeting Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Programmed Death 1 (PD-1)/Programmed Death Ligand-1 (PD-L1) demonstrated a relevant clinical value in a large number of solid tumors, leading to an improvement of progression free survival and overall survival in comparison to standard chemotherapy. However, across different solid malignancies, the immune-checkpoints inhibitors efficacy is limited to a relative small number of patients and, for this reason, the identification of positive or negative predictive biomarkers represents an urgent need. Despite the expression of PD-L1 was largely investigated in various malignancies, (i.e., melanoma, head and neck malignancies, urothelial and renal carcinoma, metastatic colorectal cancer, and pancreatic cancer) as a biomarker for ICB treatment-patients selection, it showed an important, but still imperfect, role as positive predictor of response only in nonsmall cell lung cancer (NSCLC). Importantly, other tumor and/or microenvironments related characteristics are currently under clinical evaluation, in combination or in substitution of PD–L1 expression. In particular, tumor-infiltrating immune cells, gene expression analysis, mismatch- repair deficiency, and tumor mutational landscape may play a central role in predicting clinical benefits of CTLA-4 and/or PD-1/PD-L1 checkpoint inhibitors. In this review, we will focus on the clinical evaluation of emerging biomarkers and how these may improve the naïve vision of a single- feature patients-based selection. Hindawi 2019-04-24 /pmc/articles/PMC6507101/ /pubmed/31179334 http://dx.doi.org/10.1155/2019/9056417 Text en Copyright © 2019 Diego Signorelli et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Signorelli, Diego
Giannatempo, Patrizia
Grazia, Giulia
Aiello, Marco Maria
Bertolini, Federica
Mirabile, Aurora
Buti, Sebastiano
Vasile, Enrico
Scotti, Vieri
Pisapia, Pasquale
Cona, Maria Silvia
Rolfo, Christian
Malapelle, Umberto
Group, Immune-Oncology YOUNG
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker
title Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker
title_full Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker
title_fullStr Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker
title_full_unstemmed Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker
title_short Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker
title_sort patients selection for immunotherapy in solid tumors: overcome the naïve vision of a single biomarker
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507101/
https://www.ncbi.nlm.nih.gov/pubmed/31179334
http://dx.doi.org/10.1155/2019/9056417
work_keys_str_mv AT signorellidiego patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker
AT giannatempopatrizia patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker
AT graziagiulia patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker
AT aiellomarcomaria patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker
AT bertolinifederica patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker
AT mirabileaurora patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker
AT butisebastiano patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker
AT vasileenrico patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker
AT scottivieri patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker
AT pisapiapasquale patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker
AT conamariasilvia patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker
AT rolfochristian patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker
AT malapelleumberto patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker
AT groupimmuneoncologyyoung patientsselectionforimmunotherapyinsolidtumorsovercomethenaivevisionofasinglebiomarker